Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common numbing drug beat morphine for kidney stone pain?

NCT ID NCT07536594

Symptom relief Sponsor: Loma Linda University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares lidocaine, a numbing drug, to morphine for treating severe kidney stone pain in the emergency room. Researchers will enroll 250 adults whose pain isn't relieved by standard treatment. The goal is to see if lidocaine provides better pain relief at 30 minutes, potentially offering a safer, non-opioid option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lidocaine
What this could lead to
If lidocaine works better than morphine, it could offer a non-opioid option for kidney stone pain, helping to reduce opioid misuse.
What could go wrong
This is a small, early-stage trial with only 250 people. Previous promising results from Iran may not hold up in a more diverse U.S. population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: In order to be eligible for inclusion in the study, an individual must meet all of the following criteria: * Age ≥ 18 years at time of visit * Able and willing to consent for participation in study * Documentation of suspected renal colic as primary complaint as evidenced by reported flank pain, back pain, abdominal pain, or groin pain, or as determined by the treating clinician * Requires additional treatment due to inadequate analgesia or clinical suspicion of unsafe discharge secondary to pain after initial treatment with parenteral ketorolac Exclusion Criteria: Any individual who meets any of the following criteria will be excluded from participation in this study: * Age \< 18 years * Use of analgesia for renal colic within 6 hours prior to clinician evaluation * Inability or unwillingness to consent for participation in study * Experienced a severe adverse event that required clinician intervention after initial treatment with parenteral ketorolac * Documented history of allergic or anaphylactic reaction to NSAIDs, lidocaine, or morphine * Documented history of cardiac arrhythmias * Documented history of chronic use of opioid medications for unrelated diagnoses * Currently pregnant * Documented history of end-stage renal or hepatic dysfunction * Clinical contraindications to NSAIDs, lidocaine, or morphine per clinician discretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney stones, urolithiasis, hypocitraturia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Kidney Calculi nephrolithiasis Renal Colic urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney stones, urolithiasis, hypocitraturia Opioid use during medical care Renal colic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.